NCT07532603

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Lichen Planopilaris

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 342 (estimated)
• Sponsor: Priovant Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris

Conditions

• Lichen Planopilaris

Interventions

Type	Name	Description
DRUG	Oral Brepocitinib	Oral
DRUG	Placebo	Oral

Timeline

• Start date: 2026-03-19
• Primary completion: 2028-12-31
• Completion: 2029-07-31
• First posted: 2026-04-16
• Last updated: 2026-04-16

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study